JNJ-47910382

DRUG2 trials

Sponsors

Janssen R&D Ireland

Conditions

Chronic Hepatitis C InfectionHepatitis C Virus Infection

Phase 1

A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

CompletedNCT01482611

Janssen R&D IrelandHepatitis C Virus Infection

Start: 2011-11-30End: 2012-04-30Updated: 2013-02-20

Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

TerminatedNCT01651767

Janssen R&D IrelandChronic Hepatitis C Infection

Start: 2012-08-31End: 2013-06-30Updated: 2014-05-12